Medivir AB announced that it has appointed Dr. Tom Morris as interim Chief Medical Officer effective October 5, 2020. Dr. Morris will report to CEO Yilmaz Mahshid and join the Medivir Executive Team. Tom Morris has more than 20 years of experience within drug development, mostly in oncology. Previously employed at Medeval Ltd. and more recently at AstraZeneca. He has overseen the clinical development of several global drug programs, interacting with regulatory agencies, external clinical experts and academic groups worldwide.